Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
This product will be manufactured by Indoco Remedies at their manufacturing facility located at Goa
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
Ivabradine Tablets, 5 mg and 7.5 mg had annual sales of USD 136.5 mn in the United States
The receipt of this permission paves way for the launch of BREZTRI AEROSPHERE in India
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
The product is expected to be launched in FY25
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
The Product will be manufactured at the company's facility in Bengaluru
Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Decision on EU marketing authorisation expected for momelotinib by early 2024
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
The product will be manufactured at Lupin’s Nagpur facility in India
Subscribe To Our Newsletter & Stay Updated
